Shionogi & Co., Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Shionogi & Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Shionogi & Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Shionogi & Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shionogi & Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Shionogi & Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Shionogi & Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Shionogi & Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Shionogi & Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Shionogi & Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Shionogi & Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Shionogi & Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shionogi & Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Shionogi & Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Shionogi & Co., Ltd. Snapshot 7
Shionogi & Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Shionogi & Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Shionogi & Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Shionogi & Co., Ltd. - Pipeline Products Glance 17
Shionogi & Co., Ltd. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Shionogi & Co., Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Shionogi & Co., Ltd. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Shionogi & Co., Ltd. - Drug Profiles 23
Actair 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ospemifene 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
lusutrombopag 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
naldemedine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
oxycodone hydrochloride ER 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
S-555739 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
S-588410 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
S-646240 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
S-649266 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
S-707106 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
S-222611 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
S-488210 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drug for Japanese Cedar Pollen Allergy 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
S-010887 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
S-117957 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
S-120083 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
S-237648 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Abuse Deterrent Combination Hydrocodone Program 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
hydrocodone bitartrate ER 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Agonize CB2 for Pruritus 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Antagonize NPY5R for Obesity 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules for Mycobacterium Tuberculosis 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Shionogi & Co., Ltd. - Pipeline Analysis 48
Shionogi & Co., Ltd. - Pipeline Products by Target 48
Shionogi & Co., Ltd. - Pipeline Products by Route of Administration 50
Shionogi & Co., Ltd. - Pipeline Products by Molecule Type 51
Shionogi & Co., Ltd. - Pipeline Products by Mechanism of Action 52
Shionogi & Co., Ltd. - Recent Pipeline Updates 54
Shionogi & Co., Ltd. - Dormant Projects 57
Shionogi & Co., Ltd. - Discontinued Pipeline Products 58
Discontinued Pipeline Product Profiles 58
ADX-415 58
doripenem 58
lusutrombopag 58
S-234462 58
S-288310 59
S-444823 59
S-488410 59
S-5751 59
S-777469 59
S-8510 59
teceleukin 59
velneperit 60
Shionogi & Co., Ltd. - Company Statement 61
Shionogi & Co., Ltd. - Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Shionogi & Co., Ltd. - Key Manufacturing Facilities 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Shionogi & Co., Ltd., Key Information 7
Shionogi & Co., Ltd., Key Facts 7
Shionogi & Co., Ltd. - Pipeline by Indication, 2014 9
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2014 11
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2014 12
Shionogi & Co., Ltd. - Partnered Products in Pipeline, 2014 13
Shionogi & Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14
Shionogi & Co., Ltd. - Out-Licensed Products in Pipeline, 2014 15
Shionogi & Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16
Shionogi & Co., Ltd. - Pre-Registration, 2014 17
Shionogi & Co., Ltd. - Phase III, 2014 18
Shionogi & Co., Ltd. - Phase II, 2014 19
Shionogi & Co., Ltd. - Phase I, 2014 20
Shionogi & Co., Ltd. - Preclinical, 2014 21
Shionogi & Co., Ltd. - Discovery, 2014 22
Shionogi & Co., Ltd. - Pipeline by Target, 2014 49
Shionogi & Co., Ltd. - Pipeline by Route of Administration, 2014 50
Shionogi & Co., Ltd. - Pipeline by Molecule Type, 2014 51
Shionogi & Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 53
Shionogi & Co., Ltd. - Recent Pipeline Updates, 2014 54
Shionogi & Co., Ltd. - Dormant Developmental Projects,2014 57
Shionogi & Co., Ltd. - Discontinued Pipeline Products, 2014 58
Shionogi & Co., Ltd., Other Locations 62
Shionogi & Co., Ltd., Subsidiaries 63
Shionogi & Co., Ltd., Key Manufacturing Facilities 65